CT-0596

N/A

Report date: 2026/01/06 13:26:16

Base Information

Drug NameCT-0596
Drug Alias NameCT0596CT-0596
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionT lymphocyte replacementsImmunologic cytotoxicityB-cell maturation protein modulators
TargetsB-cell maturation protein
Therapy Area/IndicationsMultiple MyelomaLeukemia, Plasma Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesCarsgen Biomedicine (Shanghai) Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesCarsgen Biomedicine (Shanghai) Co Ltd
Inactive CompaniesN/A
Active IndicationsMultiple MyelomaLeukemia, Plasma Cell
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A